ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of ...

In addition, following the FDA’s acceptance of the IND application for KPI-012 and under the terms of the private placement announced on November 28, 2022, Kala today sold an aggregate of 43,478 ...

Kala shares soared $9.45, or 266%, Wednesday to $13.52. The agency's acceptance of Kala's drug application "is an important milestone" for the company as it works to improve outcomes for those ...